4-[2-乙基-1-(4-羟基苯基)丁-1-烯基]苯酚 | 16174-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[2-乙基-1-(4-羟基苯基)丁-1-烯基]苯酚
• 英文名称: 1,1-bis(4-hydroxyphenyl)-2-ethylbut-1-ene
• 英文别名: 4,4'-(2-ethylbut-1-ene-1,1-diyl)diphenol；1,1-bis(4-hydroxyphenyl)-2-ethyl-1-butene；1,1-Bis(p-hydroxyphenyl)-2-ethyl-1-buten；2-Ethyl-1,1-bis-(4-hydroxy-phenyl)-buten-(1)；2-Aethyl-1,1-bis-(4-hydroxy-phenyl)-but-1-en；2-ethyl-1,1-bis-(4-hydroxy-phenyl)-but-1-ene；3-(4.4'-Dihydroxy-benzhydryliden)-pentan；4,4'-(2-Ethyl-1-butenylidene)diphenol；4-[2-ethyl-1-(4-hydroxyphenyl)but-1-enyl]phenol
• CAS: 16174-47-3
• 化学式: C₁₈H₂₀O₂
• 分子量: 268.356
• InChiKey: AWIVCGHUJHEQNV-UHFFFAOYSA-N

物化性质

• 熔点：
  170-173 °C
• 沸点：
  150-160 °C
• 密度：
  1.104±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2907299090

反应信息

• 作为反应物：
  描述：

  4-[2-乙基-1-(4-羟基苯基)丁-1-烯基]苯酚 在 sodium hydroxide 、 aluminum nickel 作用下， 生成 4-[2-乙基-1-(4-羟基苯基)丁基]苯酚
  参考文献：
  名称：

  Miquel, Acta Chemica Scandinavica (1947), 1958, vol. 12, p. 274,280

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-Bis-(4-methoxy-phenyl)-2-ethyl-but-1-en 在 氢氧化钾 作用下， 生成 4-[2-乙基-1-(4-羟基苯基)丁-1-烯基]苯酚
  参考文献：
  名称：

  Foeldi; Demjen, Chemische Berichte, 1941, vol. 74, p. 930,933

  摘要：

  DOI：

文献信息

• Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
  作者：Wei Lv、Jinzhong Liu、Todd C. Skaar、David A. Flockhart、Mark Cushman

  DOI：10.1021/jm501218e

  日期：2015.3.26

  Both selective estrogen receptor modulators and aromatase inhibitors are widely used for the treatment of breast cancer. Compounds with both aromatase inhibitory and estrogen receptor modulatory activities could have special advantages for treatment of breast cancer. Our previous efforts led to the discovery of norendoxifen as the first compound with dual aromatase inhibitory and estrogen receptor binding activities. To optimize its efficacy and aromatase selectivity versus other cytochrome P450 enzyme, a series of structurally related norendoxifen analogues were designed and synthesized. The most potent compound, 4'-hydroxynorendoxifen (10), displayed elevated inhibitory potency against aromatase and enhanced affinity for estrogen receptors when compared to norendoxifen. The selectivity of 10 for aromatase versus other cytochrome P450 eniymes was also superior to norendoxifen. 4'-Hydroxynorendoxifen is therefore an interesting lead for further development to obtain new anticancer agents of potential value for the treatment of breast cancer.
• JP6176615
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of Unsymmetrical Diphenylalkenes¹
  作者：Jean-François Miquel、Hans Wåhlstam、Knut Olsson、Bertil Sundbeck

  DOI：10.1021/jm00342a033

  日期：1963.11
• A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor
  作者：Makoto Hasegawa、Yukari Yasuda、Makoto Tanaka、Kenya Nakata、Eri Umeda、Yanwen Wang、Chihiro Watanabe、Shoko Uetake、Tatsuki Kunoh、Masafumi Shionyu、Ryuzo Sasaki、Isamu Shiina、Tamio Mizukami

  DOI：10.1016/j.ejmech.2013.11.009

  日期：2014.1

  In a survey of nonpeptide noncovalent inhibitors of the human 20S proteasome, we found that a novel tamoxifen derivative, RID-F (compound 6), inhibits all three protease activities of the proteasome at submicromolar levels. Structure activity relationship studies revealed that a RID-F analog (RID-F-S*4, compound 25) is the smallest derivative compound capable of inhibiting proteasome activity, with a potency similar to that of RID-F. Kinetic analyses of the inhibition mode and competition experiments involving biotin-belactosin A (a proteasome inhibitor) binding indicated that the RID-F derivatives interact with the protease subunits in a different manner. Culturing of human cells with these compounds resulted in accumulation of ubiquitinated proteins and induction of apoptosis. Thus, the RID-F derivatives may be useful lead chemicals for the generation of a new class of proteasome inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.
• JP6754125
  申请人：——

  公开号：——

  公开（公告）日：——